Rock Springs Capital Management’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-626,526
| Closed | -$29.7M | – | 100 |
|
|
2025
Q3 | $29.7M | Sell |
626,526
-14,000
| -2% | -$678K | 1.74% | 20 |
|
|
2025
Q2 | $34.2M | Sell |
640,526
-32,233
| -5% | -$1.46M | 2.13% | 14 |
|
|
2025
Q1 | $27.2M | Sell |
672,759
-273,740
| -29% | -$11.6M | 1.56% | 24 |
|
|
2024
Q4 | $26.3M | Buy |
946,499
+13,100
| +1% | +$397K | 1% | 35 |
|
|
2024
Q3 | $26.8M | Sell |
933,399
-140,862
| -13% | -$3.67M | 0.87% | 44 |
|
|
2024
Q2 | $25.2M | Sell |
1,074,261
-225,627
| -17% | -$4.83M | 0.76% | 43 |
|
|
2024
Q1 | $32.8M | Buy |
1,299,888
+218,824
| +20% | +$5.26M | 0.83% | 41 |
|
|
2023
Q4 | $25.2M | Sell |
1,081,064
-338,086
| -24% | -$6.67M | 0.62% | 47 |
|
|
2023
Q3 | $71.8M | Sell |
1,419,150
-131,604
| -8% | -$6.13M | 1.92% | 15 |
|
|
2023
Q2 | $72.4M | Buy |
1,550,754
+96,500
| +7% | +$4.42M | 1.72% | 20 |
|
|
2023
Q1 | $55.6M | Buy |
1,454,254
+53,600
| +4% | +$2.39M | 1.33% | 27 |
|
|
2022
Q4 | $76.8M | Buy |
1,400,654
+30,681
| +2% | +$1.31M | 1.85% | 20 |
|
|
2022
Q3 | $46.6M | Buy |
1,369,973
+690,459
| +102% | +$10.6M | 1.2% | 26 |
|
|
2022
Q2 | $6.42M | Buy |
679,514
+44,300
| +7% | +$462K | 0.19% | 92 |
|
|
2022
Q1 | $9.01M | Buy |
635,214
+48,113
| +8% | +$842K | 0.23% | 85 |
|
|
2021
Q4 | $12.4M | Buy |
587,101
+18,400
| +3% | +$408K | 0.29% | 84 |
|
|
2021
Q3 | $12.7M | Buy |
568,701
+40,100
| +8% | +$908K | 0.27% | 96 |
|
|
2021
Q2 | $13.1M | Buy |
528,601
+7,430
| +1% | +$209K | 0.26% | 100 |
|
|
2021
Q1 | $15.1M | Buy |
521,171
+5,800
| +1% | +$176K | 0.33% | 85 |
|
|
2020
Q4 | $13.3M | Buy |
515,371
+92,331
| +22% | +$2.57M | 0.28% | 101 |
|
|
2020
Q3 | $13M | Buy |
423,040
+180,055
| +74% | +$6.29M | 0.33% | 85 |
|
|
2020
Q2 | $6.05M | Buy |
242,985
+17,985
| +8% | +$411K | 0.17% | 124 |
|
|
2020
Q1 | $4.77M | Hold |
225,000
| – | – | 0.2% | 102 |
|
|
2019
Q4 | $4.99M | Hold |
225,000
| – | – | 0.16% | 109 |
|
|
2019
Q3 | $5.12M | Hold |
225,000
| – | – | 0.2% | 102 |
|
|
2019
Q2 | $4.31M | Buy |
+225,000
| New | +$4.26M | 0.16% | 110 |
|
Other funds holding AKRO
Rock Springs Capital Management's AKRO Position: Q4 2025 in Review
Rock Springs Capital Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 626,526 shares — an estimated $29.7M sold.
Rock Springs Capital Management first reported a position in AKRO in Q2 2019 and held it in 26 quarters. The position peaked at $76.8M in Q4 2022. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- Rock Springs Capital Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- Rock Springs Capital Management sold 626,526 Akero Therapeutics shares in Q4 2025, an estimated $29.7M.
- Rock Springs Capital Management first reported a position in Akero Therapeutics in Q2 2019 and held it in 26 quarters.
- Rock Springs Capital Management's Akero Therapeutics position peaked at $76.8M in Q4 2022.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on Rock Springs Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.